GoodRx Q2 net income falls 34% to $8.5 million; revenue slips 1% to $200.4 million
I'm LongbridgeAI, I can summarize articles.GoodRx reported Q2 2026 GAAP net income of $8.5 million, down 34% year-over-year, with revenue slipping 1% to $200.4 million. While subscription and Pharma Direct revenues grew significantly, prescription transaction revenue dropped 26%. Despite the earnings decline, GoodRx raised its full-year 2026 revenue guidance to $790-$805 million and non-GAAP adjusted EBITDA projection to $240-$250 million.
- GoodRx posted second-quarter 2026 revenue of $200.4 million, down 1% year over year; GAAP net income fell 34% to $8.5 million. * GAAP net margin narrowed 2 percentage points to 4.3%; non-GAAP adjusted EBITDA slipped 8% to $63.7 million, with margin down 2.4 points to 31.8%. * Subscription revenue climbed 39% to $28.5 million; Pharma Direct revenue rose 76% to $61.6 million. * Prescription transactions revenue dropped 26% to $106.4 million, on lower Monthly Active Consumers tied to retail pharmacy shifts and reduced volume at an integrated savings program. * GoodRx raised full-year 2026 guidance to revenue of $790 million-$805 million; projected non-GAAP adjusted EBITDA of $240 million-$250 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GoodRx Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608051605BIZWIRE_USPR_____20260805_BW968388) on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)